Deprelio

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deprelio

Property Description
Active ingredient Amitriptyline Hydrochloride
Form Tablet (Oral), Solution (Injection)
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Depression, Chronic Pain Syndromes
Origin Synthetic Chemical Compound

What is Deprelio and Its Medical Class?

Deprelio is a medicinal product containing the active ingredient Amitriptyline Hydrochloride, which belongs to the therapeutic class of Tricyclic Antidepressants (TCAs). This classification signifies it as a prescription-only, synthetic psychoactive compound whose primary action is on the central nervous system. This medication is clinically recognized for its effectiveness in rebalancing certain chemical messengers in the brain and nerves, and is structurally categorized as a tertiary amine, distinct within the TCA family.


The Tricyclic Antidepressant class is named for the characteristic three-ring chemical structure of its compounds. Its mechanism involves the potent inhibition of the reuptake of key neurotransmitters, primarily serotonin and norepinephrine. The therapeutic effects of the drug stem from this specific action, which allows more of these natural calming and mood-lifting messengers to be available to the nerve cells.


Composition and Source: Is Deprelio Natural or Synthetic?

Deprelio is a single-ingredient product featuring the fully synthetic compound Amitriptyline Hydrochloride. It is typically supplied in its standard dosage form as a tablet intended for oral administration, though a less common but important differentiating factor is the availability of a sterile aqueous solution for intramuscular injection. The substance is manufactured through chemical synthesis, which ensures consistency and precise control over its purity and potency.


General Use: What Conditions Does Deprelio Address?

The general purpose of medication containing Amitriptyline is to help relieve symptoms associated with imbalances in nervous system chemistry, particularly those related to mood disorders and certain pain conditions. Its ability to modulate nerve signals is well-established in clinical practice. This fundamental action means the medication is used broadly to assist patients suffering from depressive illness and in various pain syndromes, such as nerve-related discomfort. Its overall therapeutic goal is to stabilize the central nervous system.

What side effects are possible with Deprelio?

Possible Side Effects and Safety Information for Deprelio

This section outlines the officially documented adverse reactions and safety constraints for Deprelio, strictly based on government regulatory labeling (e.g., FDA, EMA).

Adverse Reaction Scope

Key adverse reaction categories: The safety profile includes common anticholinergic, sedative, and cardiovascular effects, alongside the recognized risk of emergent suicidality with antidepressant use.

Frequency Classification Example Side Effects
Very Common (1/10) Headache, Somnolence
Common (1/100 to < 1/10) Dizziness, Dry Mouth, Constipation, Nausea, Weight Gain
Uncommon (1/1,000 to < 1/100) Hypersensitivity reactions, Urinary retention
Rare (1/10,000 to < 1/1,000) Jaundice, Agranulocytosis, Paralytic ileus

System-organ classes involved: Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Cardiac Disorders are the main organ classes in the regulatory safety documentation.

Serious adverse reactions (as documented in regulatory sources):

  • Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (up to age 24) particularly early in treatment or following dose changes (often highlighted with a Boxed Warning).
  • Severe Cardiac Events including arrhythmias, Torsade de Pointes, and QT prolongation.
  • Serotonin Syndrome, especially when co-administered with other serotonergic agents, which may present as mental status changes, autonomic instability, and neuromuscular changes.

Safety-Related Restrictions

Population-specific safety considerations: The label advises caution in older adults due to increased susceptibility to anticholinergic and cardiovascular effects. It is generally contraindicated in patients with a recent myocardial infarction or severe liver disease.

Context-of-use safety notes: Patients must be monitored for suicidal ideation upon initiation or dose adjustment. Due to the potential for drowsiness and impaired judgment, patients are cautioned against driving or operating machinery.

Regulatory safety summary: The official safety profile requires mandatory patient monitoring due to the risk of serious events like cardiac complications and emergent suicidality, while classifying events such as dry mouth and drowsiness as common and expected. This framework distinguishes critical, rare safety constraints from non-serious, frequent adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Deprelio (Amitriptyline) is considered a very serious event with the potential for life-threatening outcomes and requires immediate medical attention, even if symptoms are not fully apparent. In adults, ingestion of 750 mg or more may result in severe toxicity. The risk of toxicity is significantly increased by the simultaneous ingestion of alcohol or other psychotropic medicines.

Documented Overdose Presentations

Symptoms appear rapidly and primarily affect the central nervous and cardiovascular systems. Key manifestations include:

  • Cardiovascular: Irregular or rapid heart rate (tachycardia, arrhythmias), low blood pressure (hypotension), and shock. Continuous cardiac monitoring (ECG) is advised for 3–5 days.
  • Central Nervous System (CNS): Coma, stupor, seizures/convulsions, agitation, and delirium. The effects of the overdose may be compounded by anticholinergic symptoms like dry mouth, blurred vision, and inability to urinate.

Required Emergency Actions

Seek medical help right away. Patients should be urgently admitted to a hospital, often requiring an intensive care unit (ICU) for supportive and symptomatic treatment. Treatment focuses on securing the patient's airway, breathing, and circulation (ABCs). Patients displaying any signs of toxicity must be monitored for a minimum of 12 hours. Due to the rapid and life-threatening nature of the effects, calling local emergency services or a poison control center is essential immediately upon suspicion of an overdose.

Therapeutic Uses of Deprelio

What Deprelio Treats: Main Uses and Benefits

Deprelio is commonly used for managing certain distressing symptoms across several key therapeutic domains, applied across domains where additional symptomatic support is needed. Its application is relevant within conditions like depressive illness, various chronic pain syndromes, and in the prophylaxis of certain headaches.

The medication is commonly used to help with the pronounced symptoms of depressive illness, offering symptomatic relief for persistent low mood and loss of interest. It is also applied in addressing chronic nerve-related discomfort, which includes managing symptoms such as burning, shooting, or electric-shock-like pain, and is relevant for easing associated sleep disturbances that interfere with daily functioning.

This supportive approach is considered relevant in clinical settings marked by heightened patient distress: it supports general well-being during symptomatic phases and may assist with maintaining functional stability when symptoms intensify.


Quick Fact: Support for Symptoms of Chronic Pain and Sleep

Deprelio may assist with easing symptoms that create noticeable physiological strain, which contributes to improved comfort during periods of heightened symptoms. It is relevant in situations where symptoms cluster into patterns requiring supportive management, such as chronic neuropathic pain paired with sleep interference.

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population/Condition Regulatory Status (Example Authority)
Contraindicated Recent Myocardial Infarction (Heart Attack) Must Not Use (FDA, Health Canada)
Contraindicated Concomitant Monoamine Oxidase Inhibitor (MAOI) Use Prohibited (FDA, UK SmPC)
Contraindicated Severe Liver Disease or Heart Block Prohibited (UK SmPC, Health Canada)
Not Recommended Children under 12 (for depression/pain) Safety Not Established (FDA)
Conditional Use Older Adults (Geriatric Patients) Requires Lower Doses/Close Monitoring (FDA, UK SmPC)

Official Eligibility Statements

The eligibility for Deprelio (Amitriptyline) is strictly defined by regulatory documents. Adults are the primary approved population. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the drug, or those in the acute recovery phase following a myocardial infarction. Absolute prohibitions also apply to concomitant use with a Monoamine Oxidase Inhibitor (MAOI). Use in the pediatric population is highly restricted; for treatment of depression, use in children under 12 years of age is officially not recommended as safety and efficacy have not been established. Patients with severe liver impairment or pre-existing disorders of cardiac rhythm are also non-eligible. During pregnancy and lactation, use is generally restricted, and the decision to use must balance the potential benefit to the mother against the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Deprelio is known to interact with several classes of medicinal products, requiring specific precautions and contraindications.

Monoamine Oxidase Inhibitors (MAOIs): Concurrent use of Deprelio and MAOIs intended for psychiatric disorders is contraindicated. This includes MAOIs such as linezolid or intravenous methylene blue. Combining these medications carries a risk of severe reactions, including hyperpyretic crises, convulsions, and death. A minimum waiting period of 14 days must pass between discontinuing an MAOI and starting Deprelio, and vice versa.

Serotonergic Drugs: Co-administration with other serotonergic agents, such as triptans, fentanyl, tramadol, lithium, St. John’s Wort, and other antidepressants (SSRIs/SNRIs), increases the risk of developing a potentially life-threatening Serotonin Syndrome. If symptoms occur, Deprelio and the interacting agent must be discontinued immediately.

CNS Depressants: Deprelio may enhance the effects of Central Nervous System (CNS) depressants, including alcohol and barbiturates. Patients should be informed of this risk of potentiation. Deprelio may also block the antihypertensive action of certain medications like guanethidine. Close supervision is also required when the product is administered with thyroid medication, as it may enhance the response to the thyroid drug. Drugs that inhibit the CYP2D6 enzyme may require a lower dose of Deprelio to avoid toxicity.

Mechanism of Action

How Deprelio Works: A Mechanistic Overview

Deprelio's primary action involves targeting the reuptake mechanisms of key neurotransmitters, specifically serotonin and norepinephrine, to prolong their presence and activity in the synaptic cleft. This interaction with the neuronal transporters modifies the activity in dysregulated signaling processes within the monoaminergic system, resulting in altered signaling dynamics within targeted neural pathways.

Beyond its core function, Deprelio exerts a secondary influence by interacting with several other receptor and enzyme systems, including certain adrenergic and histaminic sites. This multi-target mechanism modulates various upstream and downstream molecular steps, contributing to the modification of activity driven by distinct signaling patterns across central and peripheral pathways.

The initial receptor engagement triggers slower, time-dependent intracellular cascades that alter receptor sensitivity and gene expression over time. This crucial step engages mechanisms influencing the feedback regulation of nerve cells, leading to long-term physiological adjustments that engender changes in the magnitude of neural responses.

Dosage and Administration Information

How to Use Deprelio

Deprelio (Amitriptyline) is administered according to a structured protocol. The primary and standard method of administration is via the oral route as a tablet, though an intramuscular injection route is recognized for use when oral intake is temporarily not possible.

Dosing and Schedule Patterns

Treatment is initiated at a low starting dose which is then gradually titrated (increased) to a daily maintenance level. For most adults, this typically begins in the 25 mg to 75 mg range, increasing in 25 mg increments every five to seven days until a daily maintenance dose is achieved, generally not exceeding 150 mg for outpatient care. Due to the medication’s properties, the entire daily dose is often taken as a single dose at bedtime. The medication can be taken with or without food, and tablets must be swallowed whole with water.

Population-Specific Use and Duration

Specific dosage modifications are utilized for certain patient groups. Older adults should begin with a significantly lower initial dose, often starting at 10 mg to 25 mg daily. Use in children is generally not recommended for depression, but the drug has specific, lower-dose approval for nocturnal enuresis in children aged six and above. Maintenance treatment should continue for three to six months or longer after symptomatic improvement to prevent recurrence. A critical usage rule is that the dose must be gradually reduced (tapered) when treatment is concluded and must never be stopped suddenly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deprelio

The evidence base for Deprelio is derived from numerous research projects, including historical and contemporary clinical trials, and comprehensive Systematic Reviews, supported by authoritative governmental and peer-reviewed sources. This overview summarizes what those studies examined and where the research landscape still has limits.

Evidence for Use in Depressive Illness

Research exploring short-term symptom changes in adults with depressive illness primarily includes a large volume of Randomized Controlled Trials (RCTs) and supporting meta-analyses. These studies monitored outcomes related to systemic or functional imbalance by using validated clinical scales to measure the change in overall depressive symptom scores. Findings describe patterns observed in the studies where the measured change in symptoms, when compared to a non-active treatment (placebo), was associated with consistent measurements over the short-term follow-up periods examined. A recognized limitation is the historical nature of many original efficacy trials; their methodology reporting is often variable compared to today's standards.

Evidence for Use in Chronic Pain Syndromes

The research base includes various RCTs and systematic reviews that focused on outcomes related to physical discomfort in adults with chronic neuropathic pain (nerve-related pain). Studies monitored patient-reported outcomes describing perceived discomfort and evaluated related secondary outcomes such as changes in associated sleep disturbances. Data show patterns related to the existing trials, which described a pattern of change in pain intensity measurements over the short follow-up period examined. Scientific reviews note that while the medicine was observed in these trials, the evidence quality varies across studies, with a significant number of small-sample, older trials.

Evidence in Specific Patient Populations

Most research was studied for adult populations across all indications. A major limitation is that data for certain groups remain insufficient. Scientific reviews indicate that the long-term effects are not fully established and data are still emerging regarding the efficacy and safety for children and adolescents (under 18 years) across all conditions, including pain and headache prophylaxis.

Key Studies & References Expert Review: Amitriptyline (WHO Review on Therapeutic Role)

Frequently Asked Questions (FAQ)

Common questions about Deprelio (FAQ)


Q: Does Deprelio make you sleepy?

Official product information indicates that somnolence (sleepiness), sedation, and fatigue were commonly reported adverse reactions in clinical trials. Patients experiencing these effects should exercise caution when performing tasks requiring mental alertness, as noted in the label.


Q: What is the recommended storage temperature for Deprelio?

Regulatory documents state that Deprelio tablets should be stored at 20°C to 25°C (68°F to 77°F). Brief temperature excursions are permitted, meaning the medicine can be exposed to temperatures between 15°C and 30°C (59°F and 86°F) for short periods.


Q: Can I drink alcohol while taking Deprelio?

Official product monographs advise that the concomitant use of Deprelio with alcohol should be avoided. This is because alcohol can increase the risk of central nervous system (CNS) undesirable effects, such as increased sedation or sleepiness.


Q: What if I want to stop taking Deprelio?

Official health guidance recommends that treatment should not be suddenly stopped. Discontinuing Deprelio abruptly may lead to withdrawal symptoms, which can include difficulty sleeping, anxiety, tremor, nausea, and vomiting. Any changes to a treatment plan are typically discussed with a healthcare provider.


Q: Can Deprelio be used during pregnancy or breastfeeding?

Regulatory information states that Deprelio should generally not be used during pregnancy unless the expected benefit for the mother clearly outweighs any potential risk to the developing fetus. Additionally, because the medicine is excreted in human breast milk, regulatory documents indicate that women taking it should not breast-feed.


Q: What are the contraindications for Deprelio?

According to official prescribing information, Deprelio is contraindicated (should not be used) if a patient has a known hypersensitivity reaction to the active substance (Aripiprazole) or any of the inactive ingredients (excipients) in the product.

How should Deprelio be stored and disposed of?

Storage and Disposal of Deprelio (Amitriptyline Hydrochloride)

Deprelio tablets must be stored according to regulatory requirements to preserve product integrity.


Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from excessive moisture and light.
Container Keep in the original container, tightly closed.
Prohibited Do not freeze.

Child Safety and Disposal

The medication must be kept out of the reach and sight of children.

Disposal of unused or expired Deprelio should follow local regulations, prioritizing a medicine take-back program if one is available. If household disposal is necessary, the product should be mixed with an undesirable substance, sealed in a container, and placed in the trash. It is not recommended to flush this medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deprelio found in:

A-Z Index: